GHRH and GHRP-2 synergy in men blunted by abdominal fat and age, driven by IGF-I
Background
Pulsatile growth hormone secretion declines with age and is worsened by excess abdominal-visceral fat (AVF), yet the exact modulators controlling the synergistic response to combined secretagogue stimulation remain poorly characterized. GH release is orchestrated by GHRH, somatostatin, and GHRP signaling at the pituitary, but how sex steroids — testosterone and estradiol — interact with age and adiposity to shape that axis was unknown. GHRH-GHRP synergy, the markedly amplified GH pulse achieved by co-administration of both secretagogues, offers a high-resolution pharmacological probe of somatotroph reserve. Understanding what attenuates this synergy has direct relevance for diagnosing and potentially reversing age-related somatopause.
Study Design
47 healthy men (ages 18–74 yr) underwent simultaneous i.v. co-infusion of GHRH and GHRP-2 to provoke maximal synergistic GH secretion. The gonadal axis was pharmacologically suppressed with leuprolide, then subjects were randomized to receive either placebo or testosterone repletion to clamp the sex-steroid milieu, isolating hormonal effects. Baseline metabolic parameters — IGF-I, IGFBP-3, estradiol (E₂), testosterone (T), and AVF by imaging — spanned wide physiological ranges (AVF 11–349 cm²; IGF-I 115–817 µg/l). Primary endpoints were synergistic GH secretion, fasting pulsatile GH secretion, and basal (nonpulsatile) GH secretion, analyzed via stepwise forward-selection multivariate regression.
Results
GHRH-GHRP-2 synergy correlated negatively with both age and AVF (P < 0.001 for each) and positively with IGF-I (P < 0.001) and IGFBP-3 (P = 0.031). Fasting pulsatile GH secretion was negatively associated with age (P = 0.017) and positively with IGF-I (P = 0.002) and IGFBP-3 (P = 0.001). Unstimulated basal GH secretion showed positive correlations with testosterone (P = 0.015) and estradiol (P = 0.004).
AVF, IGF-I, and IGFBP-3 together explained 60% of the variability in GHRH-GHRP synergy (P < 0.001); E₂ alone accounted for 17% of basal GH variability (P = 0.007); and IGF-I explained 20% of fasting pulsatile GH variability (P = 0.002).
Multivariate analysis thus revealed highly compartmentalized control: AVF dominates synergistic peptide-driven output, estradiol governs tonic basal release, and IGF-I tracks pulsatile secretory amplitude — with each compartment operating through largely distinct determinants.
Key Findings
- AVF, IGF-I, and IGFBP-3 jointly explained 60% of GHRH-GHRP-2 synergy variability (P < 0.001)
- Estradiol accounted for 17% of basal GH secretion variability (P = 0.007)
- IGF-I alone explained 20% of fasting pulsatile GH secretion variability (P = 0.002)
- GHRH-GHRP synergy correlated negatively with AVF and age (both P < 0.001)
- Basal nonpulsatile GH secretion correlated positively with testosterone (P = 0.015) and E₂ (P = 0.004)
Why It Matters
Clinicians and biohackers using sermorelin or GHRP-2 should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. Reducing AVF before or alongside GHRH/GHRP stack protocols may be the highest-yield intervention for restoring GH axis responsiveness. The sex-steroid clamp design shows that estradiol, even in men, selectively drives basal GH tone, suggesting aromatase activity is a meaningful variable when titrating GH secretagogue regimens. Clinically, these findings argue for AVF measurement as a predictive biomarker of GHRH-GHRP response, and for IGF-I and IGFBP-3 as the best surrogate markers of pulsatile GH reserve during secretagogue therapy.
